3Elisabetta Bugianesi MD,Ester Vanni MD,Giulio Marchesini MD.NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes[J].Current Diabetes Reports.2007(3)
4Lu H,Zeng L,Liang B,et al.High prevalence of coronary heart diseasein type 2 diabetic patients with non-alcoholic fatty liver disease[].Arctic Medical Research.2009
5Farrell GC,Larter CZ.Nonalcoholic fatty liver disease: from steatosis to cirrhosis[].Hepatology.2006
6Tushuizen ME,Bunck MC,Pouwels PJ,et al.Incretin mimetics as a novel therapeutic option for hepatic steatosis〔J〕[].Liver International.2006
7Ding X,Saxena NK,Lin S,Gupta NA,Anania FA.Exendin-4 a glucagon-like protein-1 (GLP-1) receptor agonist,reverses hepatic steatosis in ob/ob mice[].Hepatology.2006
9Liu Z,Fu C,Wang W,et al.Prevalence of chronic complica-tions of type 2diabetes mellitus in outpatients-a cross sec-tional hospital based survey in urban China[].Health andQuality Life Outcomes.2010
10Yokoyama H,Yokota Y,Tada J,et al.Diabetic neuropathy is closelyassociated with arterial stiffening and thickness in Type 2 diabetes[].Diabetic Medicine.2007
